TCR² Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
- Consistent progress of TC-210 with interim update from Phase 1/2 trial anticipated in 4Q20
- Additional clinical sites to include
- Agreement with ElevateBio for additional manufacturing capacity for production of TC-210 Phase 2 clinical trial material
“The third quarter was marked by consistency in the clinical benefit provided by our lead TRuC-T cell program, TC-210, previously shown to have produced RECIST partial responses at its very first dose level, as well as the completion of a successful financing,” said
- TCR2 announced a partnership with
ElevateBio, LLC, a Cambridge, MA-based creator and operator of a portfolio of innovative cell and gene therapy companies. The agreement with ElevateBio provides TCR2 access to ElevateBio BaseCamp, its centralized 140,000 square foot, world-class cell and gene therapy manufacturing facility based in Waltham, MA.The BaseCamp partnership enables TCR2 Therapeutics to establish additional manufacturing capacity and technical capabilities in the U.S., in addition to its existing Stevenage, UK, manufacturing facility, and will support the Phase 2 expansion portion of the TC-210 Phase 1/2 clinical trial once a recommended Phase 2 dose is defined.
- TCR2 anticipates an interim update from the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for patients with mesothelin-expressing solid tumors in 4Q20.
- TCR2 anticipates an interim update from the Phase 1 portion of the TC-110 Phase 1/2 clinical trial for patients with CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia in 2021.
- TCR2 anticipates certification of its manufacturing facility in
Stevenage, UK, in 4Q20.
- TCR2 anticipates an IND filing for a third TRuC-T cell program in 2021.
- Cash Position: TCR2 ended the third quarter of 2020 with
$246.7 millionin cash, cash equivalents, and investments compared to $158.1 millionas of December 31, 2019. Net cash used in operations was $10.8 millionfor the third quarter of 2020 compared to $10.1 millionfor third quarter of 2019. TCR2 projects net cash use of $65-70 millionfor 2020.
- R&D Expenses: Research and development expenses were
$12.8 millionfor the third quarter of 2020 compared to $11.3 millionfor the third quarter of 2019. The increase in R&D expenses were primarily related to increases in headcount, activities related to the Phase 1/2 clinical trial of TC-210 and activities related to the Phase 1/2 clinical trial of TC-110.
- G&A Expenses: General and administrative expenses were
$4.4 millionfor the third quarter of 2020 compared to $3.5 millionfor the third quarter of 2019. The increase in general and administrative expenses was primarily due to an increase in personnel costs and costs associated with operations as a public company.
- Net Loss: Net loss was
$16.9 millionfor the third quarter of 2020 compared to $13.8 millionfor the third quarter of 2019, driven predominantly by increased personnel expenses.
TCR2 Therapeutics management is scheduled to participate at the following upcoming conferences.
Jefferies Virtual London Healthcare Conference: Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics, will provide a company update using a virtual platform on Wednesday, November 18, 2020at 9:40am ET Piper Sandler32nd Annual Virtual Healthcare Conference: Ian Somaiya, Chief Financial Officer of TCR2 Therapeutics, and Alfonso Quintás Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, will participate in a fireside chat using a virtual platform on Monday, November 23, 2020at 10:00am ET
This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of TC-210, timing for interim updates for the TC-210 and TC-110 clinical trials, timing for the certification of our manufacturing facility in
The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR2’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR2’s ability to secure additional manufacturing facilities; whether TCR2's cash resources will be sufficient to fund TCR2's foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR2’s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR2’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although TCR2 believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur.
Moreover, except as required by law, neither TCR2 nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR2’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR2, please visit www.tcr2.com.
Investor and Media Contact:
Director, Investor Relations and Corporate Communications
TCR2 THERAPEUTICS INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share data)
|September 30, 2020||December 31, 2019|
|Cash and cash equivalents||$||101,614||$||65,296|
|Prepaid expenses and other current assets||7,509||5,061|
|Total current assets||254,232||163,185|
|Property and equipment, net||6,201||4,926|
|Deferred offering costs||-||-|
|Liabilities and stockholders’ equity|
|Accrued expenses and other current liabilities||4,904||5,050|
|Total current liabilities||7,852||7,533|
|Additional paid-in capital||483,433||342,896|
|Accumulated other comprehensive income||191||142|
|Total stockholders’ equity||252,363||160,449|
|Total liabilities and stockholders’ equity||$||260,850||$||168,528|
TCR2 THERAPEUTICS INC.
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
|Three Months Ended
|Nine Months Ended
|Research and development||$||12,820||$||11,374||$||37,682||$||28,096|
|General and administrative||4,371||3,522||12,451||9,715|
|Total operating expenses||17,191||14,896||50,133||37,811|
|Loss from operations||(17,191||)||(14,896||)||(50,133||)||(37,811||)|
|Interest income, net||300||1,090||1,546||3,039|
|Loss before income taxes||(16,891||)||(13,806||)||(48,587||)||(34,772||)|
|Accretion of redeemable convertible preferred stock to redemption value||-||-||-||$||(49,900||)|
|Net loss attributable to common stockholders||$||(16,922||)||$||(13,806||)||$||(48,673||)||$||(84,672||)|
|Per share information|
|Net loss per share of common stock, basic and diluted||$||(0.56||)||$||(0.58||)||$||(1.86||)||$||(4.21||)|
|Weighted average shares outstanding, basic and diluted||30,340,355||23,874,593||26,158,040||20,125,955|
TCR2 THERAPEUTICS INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
|Nine Months Ended September 30,|
|Adjustments to reconcile net loss to cash used in operating activities:|
|Depreciation and amortization||1,114||558|
|Stock-based compensation expense||6,186||4,597|
|Deferred tax liabilities||86||-|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other current assets||(2,449||)||(3,615||)|
|Accrued expenses and other liabilities||(114||)||1,697|
|Cash used in operating activities||(43,240||)||(31,046||)|
|Purchases of equipment||(2,523||)||(3,060||)|
|Purchases of investments||(162,147||)||(126,534||)|
|Proceeds from sale or maturity of investments||109,916||82,990|
|Cash used in investing activities||(54,754||)||(46,604||)|
|Proceeds from public offering of common stock, net of issuance costs||133,570||79,121|
|Proceeds from the exercise of stock options||742||299|
|Cash provided by financing activities||134,312||79,420|
|Net change in cash, cash equivalents, and restricted cash||36,318||1,770|
|Cash, cash equivalents, and restricted cash at beginning of year||65,713||47,964|
|Cash, cash equivalents, and restricted cash at end of period||$||102,031||$||49,734|
Source: TCR2 Therapeutics